The Methodist Hospital Research Institute Division was awarded a $444,125 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "IDENTIFICATION OF LIAX BINDING PARTNERS FOR PREVENTING RESISTANCE." The grant, which runs from April 1, 2025 to March 31, 2027, will enable the research institute to study potential therapeutic targets for preventing drug resistance. As a leading academic medical center, the Methodist Hospital Research Institute Division has a track record of delivering innovative biomedical research and serving as a subcontractor on federal contracts and grants spanning therapeutic areas like cancer, neurological disorders, and infectious diseases.
Generated 3/4/25, 8:46 AM